Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 1, pp 113–122 | Cite as

CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway

  • Peifei Li
  • Keshu Shan
  • Yi Liu
  • Yu Zhang
  • Lu Xu
  • Lei XuEmail author
Original Article

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in affluent countries. Recent studies have reported that circular RNAs (circRNAs) are important regulators of hepatic steatosis. However, the role and mechanism of circRNA in NAFLD are poorly understood.

Aims

This study is to reveal the role and mechanism of circRNA in NAFLD.

Methods

Through NAFLD-related circRNA microarrays, we used real-time quantitative reverse transcription-polymerase chain reaction to screen circScd1 levels in control and test groups of mice fed a high-fat diet. RNA interference and over-expression plasmid vectors were used to manipulate the expression of circScd1, and the biological effects were evaluated by oil red staining, triglyceride detection, and western blot analysis.

Results

CircScd1 expression was significantly lower in NAFLD tissues than in control tissues. Moreover, over-expression of circScd1 significantly inhibited the formation of lipid droplets. Western blot analyses showed that the protein levels of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5) were significantly increased. However, knockdown of circScd1 significantly promoted the degree of hepatocellular lipidosis and reduced the expression levels of JAK2 and STAT5.

Conclusions

Aberrant expression of circScd1 affects the extent of hepatocellular lipidosis in NAFLD and promotes fatty liver disease via the JAK2/STAT5 pathway.

Keywords

CircScd1 Nonalcoholic fatty liver disease Steatosis Janus kinase 2 Signal transducer and activator of transcription 5 

Abbreviations

NAFLD

Nonalcoholic fatty liver disease

JAK2

Janus kinase 2

STAT5

Signal transducer and activator of transcription 5

NASH

Nonalcoholic steatohepatitis

SD

Standard diet

HFD

Fed with high-fat diet

DMEM

Dulbecco’s modified Eagle medium

FBS

Fetal bovine serum

PA

Palmitic acid

BSA

Bovine serum albumin

qRT-PCR

Real-time quantitative reverse transcription-polymerase chain reaction

GAPDH

Glyceraldehyde-3-phosphate dehydrogenase

SiRNA

Small interfering RNA

S.D.

Standard deviation

Notes

Acknowledgments

This work was supported by the Zhejiang Provincial Natural Science Foundation of China (Nos. LQ18H160015 to P.L. and LY13H030012 to L.X.), the National Natural Science Foundation of China (No. 81300703 to L.X.), and the Ningbo Natural Science Foundation of China (Nos. 2015A610183 and 2015A610178).

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Wree A, Broderick L, Canbay A, et al. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10:627–636.CrossRefGoogle Scholar
  2. 2.
    Farrell GC, Wong VW, Chitturi S. NAFLD in Asia-as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10:307–318.CrossRefGoogle Scholar
  3. 3.
    de Alwis NM, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;1:S104–S112.CrossRefGoogle Scholar
  4. 4.
    Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–2273.CrossRefGoogle Scholar
  5. 5.
    Pendino GM, Mariano A, Surace P, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology. 2005;41:1151–1159.CrossRefGoogle Scholar
  6. 6.
    Chalasani N, Younossi Z, Lavine E, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811–826.CrossRefGoogle Scholar
  7. 7.
    Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188–2195.CrossRefGoogle Scholar
  8. 8.
    Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–1832.CrossRefGoogle Scholar
  9. 9.
    Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–1523.CrossRefGoogle Scholar
  10. 10.
    Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–388.CrossRefGoogle Scholar
  11. 11.
    Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–338.CrossRefGoogle Scholar
  12. 12.
    Li P, Chen S, Chen H, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta. 2015;444:132–136.CrossRefGoogle Scholar
  13. 13.
    Wang Y, Liu J, Liu C, et al. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic beta-cells. Diabetes. 2013;62:887–895.CrossRefGoogle Scholar
  14. 14.
    Guo XY, Chen JN. circRNA_0046367 Prevents Hepatoxicity of Lipid Peroxidation: An Inhibitory Role against Hepatic Steatosis. Oxid Med Cell Longev. 2017;2017:3960197.CrossRefGoogle Scholar
  15. 15.
    Guo XY, He CX, Wang YQ, et al. Circular RNA Profiling and Bioinformatic Modeling Identify Its Regulatory Role in Hepatic Steatosis. Biomed Res Int. 2017;2017:5936171.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Hong JW, KimY Kim YE, et al. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men. Horm Metab Res. 2011;43:48–54.CrossRefGoogle Scholar
  17. 17.
    Ichikawa T, Nakao K, Hamasaki K, et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of nonalcoholic fatty liver disease. Hepatol Int. 2007;1:287–294.CrossRefGoogle Scholar
  18. 18.
    Xu L, Xu C, Yu Z, et al. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS ONE. 2012;46:504–513.Google Scholar
  19. 19.
    Cui Y, Hosui R, Sun R, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology. 2007;46:504–513.CrossRefGoogle Scholar
  20. 20.
    Sos BC, Harris C, Nordstrom SM, et al. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest. 2011;121:1412–1423.CrossRefGoogle Scholar
  21. 21.
    Shi SY, Martin RG, Duncan RE, et al. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem. 2012;287:0277–10288.Google Scholar
  22. 22.
    Li H, Tao R, Wang J, et al. Upregulation of miR-375 level ameliorates morphine analgesic tolerance in mouse dorsal root ganglia by inhibiting the JAK2/STAT3 pathway. J Pain Res. 2017;10:1279–1287.CrossRefGoogle Scholar
  23. 23.
    Shao Y, Ye M, Jiang X, et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. Cancer. 2014;120:3320–3328.CrossRefGoogle Scholar
  24. 24.
    Xia T, Chen S, Jiang Z, et al. Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. Sci Rep. 2015;5:13445.CrossRefGoogle Scholar
  25. 25.
    Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.CrossRefGoogle Scholar
  26. 26.
    Chen HL, Tsai TC, Tsai YC, et al. Kefir peptides prevent high-fructose corn syrup-induced nonalcoholic fatty liver disease in a murine model by modulation of inflammation and the JAK2 signaling pathway. Nutr Diabetes. 2016;6:e237.CrossRefGoogle Scholar
  27. 27.
    Nordstrom SM, Tran JL, Sos BC, et al. Disruption of JAK2 in adipocytes impairs lipolysis and improves fatty liver in mice with elevated GH. Mol Endocrinol. 2013;27:1333–1342.CrossRefGoogle Scholar
  28. 28.
    Zhang Y, Liu H, Li W, et al. CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630. Aging (Albany NY). 2017;9:1585–1594.CrossRefGoogle Scholar
  29. 29.
    He R, Liu P, Xie X, et al. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. 2017;36:145.CrossRefGoogle Scholar
  30. 30.
    Deng N, Li L, Gao J, et al. Hsa_circ_0009910 promotes carcinogenesis by promoting the expression of miR-449a target IL6R in osteosarcoma. Biochem Biophys Res Commun. 2018;495:189–196.CrossRefGoogle Scholar
  31. 31.
    Chen J, Cui L, Yuan J, et al. Circular RNA WDR77 target FGF-2 to regulate vascular smooth muscle cells proliferation and migration by sponging miR-124. Biochem Biophys Res Commun. 2017;494:126–132.CrossRefGoogle Scholar
  32. 32.
    Conn SJ, Pillman KA, Toubia J, et al. he RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125–1134.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Peifei Li
    • 1
  • Keshu Shan
    • 1
  • Yi Liu
    • 1
  • Yu Zhang
    • 2
  • Lu Xu
    • 2
  • Lei Xu
    • 1
    Email author
  1. 1.Department of GastroenterologyNingbo First HospitalNingboChina
  2. 2.Ningbo University School of MedicineNingboChina

Personalised recommendations